Sugi Predict

Sugi Predict / Compounds / SCHEMBL2723372

SCHEMBL2723372

SCHEMBL2723372

CC(C)CN1CCN(c2ccc(N)nc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 2/20 0.42
▸ MTOR P42345 2/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ GFER P55789 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ RAD52 P43351 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ NOS3 P29474 1/20 0.40
▸ NOS1 P29475 1/20 0.40
▸ CCNE1 P24864 2/20 0.39
▸ CDK2 P24941 2/20 0.39
▸ TRPC6 Q9Y210 3/20 0.38
▸ GCK P35557 2/20 0.38
▸ GCKR Q14397 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CHEK1 O14757 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29437380 1.00 PIK3CA (0.42) PIK3CAMTORKDM4EGFERGAA
SCHEMBL17055237 0.85 TRPC6 (0.41) PIK3CAMTORKDM4EGFERGAA
SCHEMBL30664067 0.83 GAA (0.62) KDM4EGFERGAARAD52MAPT
SCHEMBL611882 0.83 GAA (0.62) KDM4EGFERGAARAD52MAPT
SCHEMBL17108487 0.80 DRD2 (0.54) PIK3CAMTORKDM4EGFERGAA
SCHEMBL611676 0.80 KDM4E (0.53) PIK3CAMTORKDM4EMAPTALDH1A1
SCHEMBL30664050 0.80 KDM4E (0.53) PIK3CAMTORKDM4EMAPTALDH1A1
SCHEMBL5741708 0.79 MAPT (0.66) KDM4EGFERGAARAD52MAPT
SCHEMBL1646844 0.79 PIK3CA (0.44) PIK3CAMTORKDM4EGFERGAA
SCHEMBL25949368 0.78 CDK2 (0.45) KDM4EGFERALDH1A1L3MBTL1CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4596051-A2 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION Pharmacosmos Holding A/s (DK) 2025-08-06 — — EP disclosed
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors PHARMACOSMOS HOLDING A/S (DK) 2025-04-29 — — US disclosed
EP-2968291-B1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION PHARMACOSMOS HOLDING AS (DK) 2025-04-16 — — EP disclosed
US-20240109906-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2024-04-04 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-8598186-B2 CDK inhibitors G1 THERAPEUTICS, INC. (US) 2013-12-03 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237533-A1 CDK Inhibitors G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
EP-2632467-A1 CDK INHIBITORS G1 Therapeutics, Inc. (US) 2013-09-04 — — EP disclosed
WO-2012061156-A1 CDK INHIBITORS TAVARES FRANCIS X (US) 2012-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237534-A1 CDK INHIBITORS CDK3, CDK9, CDK6 PIK3CA 234/4885MTOR 327/4885KDM4E 331/4885
US-20240109906-A1 CDK INHIBITORS CDK3, CDK9, CDK6 PIK3CA 234/4885MTOR 327/4885KDM4E 331/4885
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION RB1, CDK4, CDKN1A PIK3CA 686/4885MTOR 259/4885KDM4E 122/4885
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors RB1, CDK4, CDK6 PIK3CA 178/4885MTOR 1566/4885KDM4E 680/4885
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY CDK6, CCNC, MCL1 PIK3CA 1598/4885MTOR 933/4885KDM4E 1333/4885
US-20130237533-A1 CDK Inhibitors CDK3, CDK9, CDK6 PIK3CA 234/4885MTOR 327/4885KDM4E 331/4885
US-20130237544-A1 CDK INHIBITORS CDK3, CDK9, CDK6 PIK3CA 234/4885MTOR 327/4885KDM4E 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.